Business Standard

Sun Pharma, 7 executives settle dispute with Sebi; pay Rs 2.92 cr

Two whistle blowers had alleged that Sun Pharma and its subsidiary Sun Pharmaceutical Laboratories diverted funds through its sole distributor in India Aditya Medisales

Sun Pharma
Premium

FILE PHOTO: A bird flies past the logo of Sun Pharma installed on the facade of its corporate office in Mumbai | Photo: Reuters

Samie Modak Mumbai
Sun Pharmaceutical Indust­ries — along with seven of its executives including Dilip Shanghvi (managing director) and Sudhir Valia (director) — has settled a pending dispute with the Securities and Exchange Board of India (Sebi) by agreeing to pay a cum­ulative penalty of Rs 2.92 crore.

Sun Pharma has agreed to pay Rs 56 lakh, while Shanghvi will pay Rs 62.3 lakh, and Valia Rs 37.4 lakh. Other individuals have agreed to pay between Rs 18.5 lakh and Rs 37.4 lakh.

The matter pertains to violation of related party norms and allegations of fund diversion. Two whistle-blowers had alleged that Sun

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in